Evidence map›Paper›PMID 37375825›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Eman S El-Wakil, Hagar F Abdelmaksoud, Majed H Wakid, Muslimah N Alsulami, Olfat Hammam, Haleema H Albohiri, Marwa M I Ghallab

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Kaempferol activity onPharmaceutical biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Advances in pharmacological and pharmaceutical sciences · 2026
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Eman S El-WakilDepartment of Parasitology, Theodor Bilharz Research Institute, Imbaba 12411, Egypt.
Hagar F AbdelmaksoudDepartment of Parasitology, Theodor Bilharz Research Institute, Imbaba 12411, Egypt.
Majed H WakidDepartment of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-4941-5373
Muslimah N AlsulamiDepartment of Biology, College of Science, University of Jeddah, Jeddah 21589, Saudi Arabia.
Olfat HammamDepartment of Pathology, Theodor Bilharz Research Institute, Imbaba 12411, Egypt.ORCID 0000-0002-4965-5804
Haleema H AlbohiriDepartment of Biology, College of Science, University of Jeddah, Jeddah 21589, Saudi Arabia.
Marwa M I GhallabDepartment of Medical Parasitology, Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
Theodor Bilharz Research Institute · EGUniversity of Jeddah · SAKafrelsheikh University · EGKing Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptosporidiosis is a serious parasitic diarrheal disease linked to the occurrence of colorectal cancer in immunocompromised patients. The FDA-approved drug nitazoxanide (NTZ) achieved a temporary effect, and relapses occur.

Indexed as

Annona muricataCryptosporidiumimmunocompromised micenitazoxanide immunohistochemistry

Identifiers

PMID37375825
PMCPMC10303196
OpenAlexW4380995330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.